245 related articles for article (PubMed ID: 21873158)
1. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M
Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno S; Kyo S; Myojo S; Dohi S; Ishizaki J; Miyamoto K; Morita S; Sakamoto J; Enomoto T; Kimura T; Oka Y; Tsuboi A; Sugiyama H; Inoue M
Anticancer Res; 2009 Nov; 29(11):4779-84. PubMed ID: 20032435
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
4. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
[TBL] [Abstract][Full Text] [Related]
5. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Dohi S; Ohno S; Ohno Y; Takakura M; Kyo S; Soma G; Sugiyama H; Inoue M
Anticancer Res; 2011 Jul; 31(7):2441-5. PubMed ID: 21873157
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
7. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.
Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H
Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734
[TBL] [Abstract][Full Text] [Related]
9. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
[TBL] [Abstract][Full Text] [Related]
10. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
[TBL] [Abstract][Full Text] [Related]
11. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
12. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
16. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
18. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
Nakajima H; Oka Y; Tsuboi A; Tatsumi N; Yamamoto Y; Fujiki F; Li Z; Murao A; Morimoto S; Hosen N; Shirakata T; Nishida S; Kawase I; Isaka Y; Oji Y; Sugiyama H
Vaccine; 2012 Jan; 30(4):722-9. PubMed ID: 22133512
[TBL] [Abstract][Full Text] [Related]
19. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H; Kawasaki K; Oka Y; Tsuboi A; Kawakami M; Ikegame K; Hoshida Y; Fujiki F; Nakano A; Masuda T; Wu F; Taniguchi Y; Yoshihara S; Elisseeva OA; Oji Y; Ogawa H; Azuma I; Kawase I; Aozasa K; Sugiyama H
Cancer Immunol Immunother; 2004 Jul; 53(7):617-24. PubMed ID: 15175906
[TBL] [Abstract][Full Text] [Related]
20. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]